Rewolucja Gordona Rustina – miejsce oznaczania markera CA125 w nadzorze nad chorymi z rakiem jajnika

• Authors: Mądry Radosław , Adamczak-Ratajczak Agnieszka
• Languages of publication: PL

Keywords

PL

rak jajnika; CA125; nadzór; wznowa

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2011
• Issue: 2
• Pages: 189-191

Contributors

author

Mądry Radosław

author

Adamczak-Ratajczak Agnieszka

References

• Aebi S, Castiglione M. (On behalf of the ESMO Guidelines Working Group). Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncology 2009; 20(Suppl.4): 21–23.
• Http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
• Van Der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5(4): 301–305.
• R ustin GJS, van der Burg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/ EORTC 55955): a randomized trial. Lancet 2010; 376(9747): 1155–1163
• Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389–393
• Parker PA, Kudelka A, Basen-Engquist K, et al. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynaecol Oncology 2006; 100: 495–500.
• Oskay-Oezcelik G, du Bois A, Fasching P, et al. What do patients think about CA-125 monitoring in the follow-up?Results from a multicenter trial in 1,060 patients with ovarian cancer. J Clin Oncol 2009; 27: abstract 552
• Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009; 20: 286–292.